Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death

Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034

(2009) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer

(2009) Jolien Tol et al.   NEW ENGLAND JOURNAL OF MEDICINE

EGFR Signals to mTOR Through PKC and Independently of Akt in Glioma

(2009) Q.-W. Fan et al.   Science Signaling

Survival of Cancer Cells Is Maintained by EGFR Independent of Its Kinase Activity

(2008) Zhang Weihua et al.   CANCER CELL

Phosphatidylinositol 3-Kinase Inhibition Broadly Sensitizes Glioblastoma Cells to Death Receptor- and Drug-Induced Apoptosis

(2008) D. Opel et al.   CANCER RESEARCH

In human endothelial cells rapamycin causes mTORC2 inhibition and impairs cell viability and function

(2008) Amelia Barilli et al.   CARDIOVASCULAR RESEARCH

Changes in Tumor Metabolism as Readout for Mammalian Target of Rapamycin Kinase Inhibition by Rapamycin in Glioblastoma

(2008) L. H. Wei et al.   CLINICAL CANCER RESEARCH

Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma

(2008) Tim F Cloughesy et al.   PLOS MEDICINE